Amgen and Memory Pharmaceuticals to Develop Neurological Drugs
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 65 (Table of Contents)
Published: 5 Nov-2005
DOI: 10.3833/pdr.v2005.i65.603 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Memory Pharmaceuticals entered into an exclusive worldwide collaboration and license agreement with Amgen to develop preclinical phosphodiesterase 10 (PDE10) inhibitors for the treatment of certain neurological and psychiatric disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS